These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 17205056

  • 1. Antitumor activity of sorafenib in FLT3-driven leukemic cells.
    Auclair D, Miller D, Yatsula V, Pickett W, Carter C, Chang Y, Zhang X, Wilkie D, Burd A, Shi H, Rocks S, Gedrich R, Abriola L, Vasavada H, Lynch M, Dumas J, Trail PA, Wilhelm SM.
    Leukemia; 2007 Mar; 21(3):439-45. PubMed ID: 17205056
    [Abstract] [Full Text] [Related]

  • 2. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J, Andreeff M.
    J Natl Cancer Inst; 2008 Feb 06; 100(3):184-98. PubMed ID: 18230792
    [Abstract] [Full Text] [Related]

  • 3. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.
    Okamoto M, Hayakawa F, Miyata Y, Watamoto K, Emi N, Abe A, Kiyoi H, Towatari M, Naoe T.
    Leukemia; 2007 Mar 06; 21(3):403-10. PubMed ID: 17230226
    [Abstract] [Full Text] [Related]

  • 4. Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
    Kancha RK, Grundler R, Peschel C, Duyster J.
    Exp Hematol; 2007 Oct 06; 35(10):1522-6. PubMed ID: 17889720
    [Abstract] [Full Text] [Related]

  • 5. Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).
    Lu JW, Wang AN, Liao HA, Chen CY, Hou HA, Hu CY, Tien HF, Ou DL, Lin LI.
    Cancer Lett; 2016 Jul 01; 376(2):218-25. PubMed ID: 27060207
    [Abstract] [Full Text] [Related]

  • 6. A novel FLT3 inhibitor FI-700 selectively suppresses the growth of leukemia cells with FLT3 mutations.
    Kiyoi H, Shiotsu Y, Ozeki K, Yamaji S, Kosugi H, Umehara H, Shimizu M, Arai H, Ishii K, Akinaga S, Naoe T.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4575-82. PubMed ID: 17671144
    [Abstract] [Full Text] [Related]

  • 7. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation.
    Metzelder S, Wang Y, Wollmer E, Wanzel M, Teichler S, Chaturvedi A, Eilers M, Enghofer E, Neubauer A, Burchert A.
    Blood; 2009 Jun 25; 113(26):6567-71. PubMed ID: 19389879
    [Abstract] [Full Text] [Related]

  • 8. Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase.
    Komeno Y, Kurokawa M, Imai Y, Takeshita M, Matsumura T, Kubo K, Yoshino T, Nishiyama U, Kuwaki T, Kubo K, Osawa T, Ogawa S, Chiba S, Miwa A, Hirai H.
    Leukemia; 2005 Jun 25; 19(6):930-5. PubMed ID: 15815726
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Irreversible pan-ERBB inhibitor canertinib elicits anti-leukaemic effects and induces the regression of FLT3-ITD transformed cells in mice.
    Nordigården A, Zetterblad J, Trinks C, Gréen H, Eliasson P, Druid P, Lotfi K, Rönnstrand L, Walz TM, Jönsson JI.
    Br J Haematol; 2011 Oct 25; 155(2):198-208. PubMed ID: 21848891
    [Abstract] [Full Text] [Related]

  • 12. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C.
    Cancer Res; 2006 Dec 15; 66(24):11851-8. PubMed ID: 17178882
    [Abstract] [Full Text] [Related]

  • 13. Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia.
    Safaian NN, Czibere A, Bruns I, Fenk R, Reinecke P, Dienst A, Haas R, Kobbe G.
    Leuk Res; 2009 Feb 15; 33(2):348-50. PubMed ID: 18573526
    [Abstract] [Full Text] [Related]

  • 14. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
    Barbarroja N, Torres LA, Rodriguez-Ariza A, Valverde-Estepa A, Lopez-Sanchez LM, Ruiz-Limon P, Perez-Sanchez C, Carretero RM, Velasco F, López-Pedrera C.
    Exp Hematol; 2010 Aug 15; 38(8):641-52. PubMed ID: 20380868
    [Abstract] [Full Text] [Related]

  • 15. The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors.
    Lierman E, Lahortiga I, Van Miegroet H, Mentens N, Marynen P, Cools J.
    Haematologica; 2007 Jan 15; 92(1):27-34. PubMed ID: 17229632
    [Abstract] [Full Text] [Related]

  • 16. FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.
    von Bubnoff N, Engh RA, Aberg E, Sänger J, Peschel C, Duyster J.
    Cancer Res; 2009 Apr 01; 69(7):3032-41. PubMed ID: 19318574
    [Abstract] [Full Text] [Related]

  • 17. Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against first-generation FLT3 tyrosine kinase inhibitors.
    Parmar A, Marz S, Rushton S, Holzwarth C, Lind K, Kayser S, Döhner K, Peschel C, Oostendorp RA, Götze KS.
    Cancer Res; 2011 Jul 01; 71(13):4696-706. PubMed ID: 21546568
    [Abstract] [Full Text] [Related]

  • 18. Metformin synergistically sensitizes FLT3-ITD-positive acute myeloid leukemia to sorafenib by promoting mTOR-mediated apoptosis and autophagy.
    Wang F, Liu Z, Zeng J, Zhu H, Li J, Cheng X, Jiang T, Zhang L, Zhang C, Chen T, Liu T, Jia Y.
    Leuk Res; 2015 Dec 01; 39(12):1421-7. PubMed ID: 26505133
    [Abstract] [Full Text] [Related]

  • 19. Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model.
    Heravi M, Tomic N, Liang L, Devic S, Holmes J, Deblois F, Radzioch D, Muanza T.
    Anticancer Drugs; 2012 Jun 01; 23(5):525-33. PubMed ID: 22357220
    [Abstract] [Full Text] [Related]

  • 20. The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.
    Augustin E, Skwarska A, Weryszko A, Pelikant I, Sankowska E, Borowa-Mazgaj B.
    Acta Pharmacol Sin; 2015 Mar 01; 36(3):385-99. PubMed ID: 25640477
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.